The UCSF-GIVI CFAR Immunology Core is dedicated to stimulating translational research that explores and defines the immunological abnormalities present in HIV infection and that promotes improvements in the care of HIV-infected patients at both domestic and international sites. To accomplish this goal, the Core offers a wide array of immunological services including multiparameter flow cytometric assays of immune cell phenotype and immune function (proliferation, cytotoxicity, cytokine production and cell signaling);specialized tissue processing of bone marrow, lymph node and gut associated lymphoid tissues plus isolation of specific subsets of lymphocytes by immunomagnetic bead or FACS sorting and analysis of downstream signaling pathways within these purified cell subsets. Overall, the Core provides four complementary lines of service including: 1) customized immune assays designed to meet individual investigator needs;2) access to state-of-the-art flow cytometry including infected and uninfected cell sorting and cell analysis;3) development and optimization of new immunological assays, technologies and related services and 4) training, mentoring and education of early-career investigators, senior investigators from other disciplines, and laboratory staff. The Core provides services from two different campus sites including the Core Immunology Laboratory located within the Division of Experimental Medicine at the San Francisco General Hospital and the Gladstone Flow Core located at Mission Bay. During the last funding period, the Immunology Core supported 80 different studies from 65 different investigators, introduced 28 new immune assays, developed sixty-five 6-12 color flow cytometry panels, contributed to 59 peer-reviewed publications, trained 45 young investigators and helped leverage more than 15 million dollars in new grant support. A new top priority for the Immunology Core involves enhancing immunological expertise and capacity in Tororo, Uganda and providing mentoring and training in translational immunology to investigators at this site. The core will also continue to evaluate and introduce new technologies to accelerate the research progress of CFAR investigators including the use of intracellular branched DNA technology for detection of latent HIV infection and the use of microparticles to stage cardiovascular disease during HIV infection.

Public Health Relevance

The Immunology Core provides state-of-the art immunology assay service and instrumentation in support of basic, translational and multidisciplinary research projects that investigate the complex interactions between HIV, the immune response to HIV, and novel therapeutic interventions aimed at modifying the immune response or eradicating latent infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-22
Application #
8485503
Study Section
Special Emphasis Panel (ZAI1-RRS-A)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
22
Fiscal Year
2013
Total Cost
$769,690
Indirect Cost
$114,699
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Joglekar, Alok V; Liu, Zhe; Weber, Jeffrey K et al. (2018) T cell receptors for the HIV KK10 epitope from patients with differential immunologic control are functionally indistinguishable. Proc Natl Acad Sci U S A 115:1877-1882
Martin, Jeremy W; Chen, Joseph C; Neidleman, Jason et al. (2018) Potent and rapid activation of tropomyosin-receptor kinase A in endometrial stromal fibroblasts by seminal plasma. Biol Reprod 99:336-348
Baxi, S M; Greenblatt, R M; Bacchetti, P et al. (2018) Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV. Pharmacogenomics J 18:245-250
Adland, Emily; Hill, Matilda; Lavandier, Nora et al. (2018) Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J Virol 92:
Burbelo, Peter D; Price, Richard W; Hagberg, Lars et al. (2018) Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir? J Infect Dis 217:1024-1032
Cohen, Stephanie E; Sachdev, Darpun; Lee, Sulggi A et al. (2018) Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV :
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Ferdin, Jana; Gori?ar, Katja; Dolžan, Vita et al. (2018) Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. PLoS One 13:e0191613
Faust, Tyler B; Li, Yang; Bacon, Curtis W et al. (2018) The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation. Elife 7:
Wong, Cherise; Gange, Stephen J; Moore, Richard D et al. (2018) Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clin Infect Dis 66:1230-1238

Showing the most recent 10 out of 1541 publications